home / stock / surf / surf news

SURF News and Press, Surface Oncology Inc. From 09/27/19

Stock Information
Company Name: Surface Oncology Inc.
Stock Symbol: SURF
Market: NASDAQ
Website: surfaceoncology.com
Menu
SURF SURF Quote SURF Short SURF News SURF Articles SURF Message Board
Get SURF Alerts

News, Short Squeeze, Breakout and More Instantly...
SURF - ENDP, INMD, LTM and NXTC among midday movers

Gainers:  LATAM Airlines Group (NYSE: LTM ) +30% . Just Energy Group (NYSE: JE ) +26% . Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH ) +20% . Tiziana Life Sciences PLC (NASDAQ: TLSA ) +20% . Contango Oil & Gas Company (NYSEMKT: MCF ) +14% . Ra Medical Systems, Inc. (NYSE: R...
SURF - Surface Oncology to Present at the Baird 2019 Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Vit...

SURF - Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors

CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology  (NASDAQ:SURF), today announced Ramy Ibrahim, M.D., will join the company’s board of directors. Dr. Ibrahim is a medical oncologist currently serving as chief medical officer and vice president of clin...

SURF - Surface Oncology EPS misses by $0.03, misses on revenue

Surface Oncology (NASDAQ: SURF ): Q2 GAAP EPS of -$0.64 misses by $0.03 . More news on: Surface Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SURF - Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2019

CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter ...

SURF - Surface Oncology to Participate in 40th Annual Goldman Sachs Global Healthcare Conference

CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Surface Oncology  (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Jeff Goater, chief executive officer, will participate...

SURF - Surface Oncology Presents Preclinical Data Further Supporting Anti-Tumor Mechanism of CD73 and CD39 Programs at Brisbane Immunotherapy 2019

Presentation provides updated in vivo efficacy data supporting adenosine reduction for cancer treatment Data also support anti-CD39 candidate’s capability to invoke both innate and adaptive immune anti-tumor activity CAMBRIDGE, Mass., May 24, 2019 (GLOBE NEWSWIRE) -- Su...
SURF - Surface Oncology to Present at Two Upcoming Healthcare Conferences

CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Surface Oncology  (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Jeff Goater, chief executive officer, will be participating ...

SURF - Surface Oncology beats by $0.29, beats on revenue

Surface Oncology (NASDAQ: SURF ): Q1 GAAP EPS of -$0.15 beats by $0.29 . More news on: Surface Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SURF - Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2019

CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the first quarter of...
Previous 10 Next 10